CENTENE CORP 8-K

What Happened

• Centene Corporation (CNC) filed an 8‑K on July 28, 2026 announcing its financial results for the second quarter ended June 30, 2026 (press release included as Exhibit 99.1). The filing also discloses that director Kenneth Burdick resigned effective July 28, 2026, and the Board elected Paul Diaz to fill the vacancy, effective the same date.

Key Details

• The Q2 2026 financial results were announced via a press release dated July 28, 2026 (Exhibit 99.1); the press release and related cover page iXBRL (Exhibit 99.2) are furnished, not filed, under Regulation FD.
• Kenneth Burdick notified the Company of his resignation on July 23, 2026; his resignation was not due to any dispute or disagreement with the Company.
• Paul Diaz was appointed to the Board effective July 28, 2026, with a term expiring at Centene’s 2027 annual meeting; he will serve on the Audit Committee and the Quality and Compliance Committee.
• Mr. Diaz’s recent experience: Managing Partner at Cressey & Company (since May 2025), President & CEO of Myriad Genetics (Aug 2020–Apr 2025), prior partner at Cressey (2016–2020), and senior roles at Kindred Healthcare (2002–2018, CEO 2004–2015). He will receive standard non‑employee director compensation as disclosed in Centene’s March 27, 2026 proxy. No related‑party transactions or special arrangements were reported.

Why It Matters

• Investors should review the July 28 press release (Exhibit 99.1) for the company’s reported quarterly results, trends in revenue or earnings, and any updated guidance—those items drive near‑term stock performance and analyst expectations.
• The board change is non‑controversial and brings a director with executive experience across healthcare services and diagnostics; his Audit and Quality & Compliance committee roles may be relevant to oversight of financial reporting and compliance matters.